Developing a Metabolic-Associated Prognostic Index for Risk Stratification and Therapeutic Guidance in Stage I Lung Adenocarcinoma via Multiomics Analysis

Our results establish MAPI as a biologically interpretable and clinically applicable tool for risk stratification and precision treatment decision making in patients with stage I LUAD.